Combination Therapy with Gossypol Reveals Synergism against Gemcitabine Resistance in Cancer Cells with High BCL-2 Expression

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wong, Foong Ying ^a   Liem, Natalia ^a   Xie, Chen ^a   Yan, Fui Leng ^a   Wong, Wing Cheong ^b   Wang, Lingzhi ^c   Yong, Wei Peng ^a,c  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b BIOINFORMATICS INSTITUTE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN 1; CASPASE 6; GEMCITABINE; GOSSYPOL; PHOSPHATIDYLINOSITOL 3 KINASE RECEPTOR 2; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN NOXA; RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BAD GENE; BCL 2 GENE; BCL XL GENE; BREAST CANCER; CALPAIN 1 GENE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CASPASE 6 GENE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; GENETIC REGULATION; HUMAN; HUMAN CELL; IC 50; NASOPHARYNX CANCER; NOXA GENE; PAKT GENE; PI3KR2 GENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STOMACH CANCER; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; DEOXYCYTIDINE; DOWN-REGULATION; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GOSSYPOL; HUMANS; INHIBITORY CONCENTRATION 50; MULTIGENE FAMILY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84870728584     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050786     Document Type: Article

References (52)

1. Dent S, Messersmith H, Trudeau M, (2008) Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res Treat 108: 319-331.
2. Natale R, (2005) A ten-year review of progress in the treatment of non-small-cell lung cancer with gemcitabine. Lung Cancer 50 (Suppl 1): S2-4.
3. Hilbig A, Oettle H, (2008) Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Rev Anticancer Ther 8: 511-523.
4. Lorusso D, Di Stefano A, Fanfani F, Scambia G, (2006) Role of gemcitabine in ovarian cancer treatment. Ann Oncol 17 (Suppl 5): v188-194.
5. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, et al. (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22: 3-10.
6. Castilla C, Congregado B, Chinchon D, Torrubia FJ, Japon MA, et al. (2006) Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 147: 4960-4967.
7. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, et al. (2005) Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 96: 287-295.
8. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, et al. (2003) Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 9: 33-41.
9. Yu B, Sun X, Shen HY, Gao F, Fan YM, et al. (2010) Expression of the apoptosis-related genes BCL-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity. J Exp Clin Cancer Res 29: 107.
10. Chun E, Lee KY, (2004) Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 315: 771-779.
11. Bold RJ, Chandra J, McConkey DJ, (1999) Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 6: 279-285.
12. Han JY, Hong EK, Choi BG, Park JN, Kim KW, et al. (2003) Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med Oncol 20: 355-362.
13. Shi X, Liu S, Kleeff J, Friess H, Buchler MW, (2002) Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62: 354-362.
14. Coutinho EM, (2002) Gossypol: a contraceptive for men. Contraception 65: 259-263.
15. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, et al. (2003) Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 46: 4259-4264.
16. Zhang M, Liu H, Guo R, Ling Y, Wu X, et al. (2003) Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 66: 93-103.
17. Zhang M, Liu H, Tian Z, Griffith BN, Ji M, et al. (2007) Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways. Life Sci 80: 767-774.
18. Chang JS, Hsu YL, Kuo PL, Chiang LC, Lin CC, (2004) Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. Clin Exp Pharmacol Physiol 31: 716-722.
19. Gilbert NE, O'Reilly JE, Chang CJ, Lin YC, Brueggemeier RW, (1995) Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci 57: 61-67.
20. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V, (2008) Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112: 1971-1980.
21. Oliver CL, Miranda MB, Shangary S, Land S, Wang S, et al. (2005) (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther 4: 23-31.
22. Bauer JA, Trask DK, Kumar B, Los G, Castro J, et al. (2005) Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther 4: 1096-1104.
23. Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Gul MK, et al. (2010) Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination. Mol Biol Rep 37: 1269-1277.
24. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, et al. (1989) Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci U S A 86: 9524-9528.
25. Lo KW, Kwong J, Hui AB, Chan SY, To KF, et al. (2001) High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 61: 3877-3881.
26. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
27. Wong WC, Loh M, Eisenhaber F, (2008) On the necessity of different statistical treatment for Illumina BeadChip and Affymetrix GeneChip data and its significance for biological interpretation. Biol Direct 3: 23.
28. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
29. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, et al. (1998) High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 9: 159-165.
30. Sartorius UA, Krammer PH, (2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97: 584-592.
31. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ, (2005) Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 56: 46-54.
32. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, et al. (2004) Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 109: 182-188.
33. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, et al. (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675-1687.
34. Macoska JA, Adsule S, Tantivejkul K, Wang S, Pienta KJ, et al. (2008)-(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro. Pharmacol Res 58: 323-331.
35. Galmarini CM, Mackey JR, Dumontet C, (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15: 875-890.
36. Bergman AM, Pinedo HM, Peters GJ, (2002) Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5: 19-33.
37. Meng Y, Tang W, Dai Y, Wu X, Liu M, et al. (2008) Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 7: 2192-2202.
38. Labi V, Grespi F, Baumgartner F, Villunger A, (2008) Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ 15: 977-987.
39. Barba-Barajas M, Hernandez-Flores G, Lerma-Diaz JM, Ortiz-Lazareno PC, Dominguez-Rodriguez JR, et al. (2009) Gossypol induced apoptosis of polymorphonuclear leukocytes and monocytes: involvement of mitochondrial pathway and reactive oxygen species. Immunopharmacol Immunotoxicol 31: 320-330.
40. Oliver CL, Bauer JA, Wolter KG, Ubell ML, Narayan A, et al. (2004) In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 10: 7757-7763.
41. Shieh JJ, Liu KT, Huang SW, Chen YJ, Hsieh TY, (2009) Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. J Invest Dermatol 129: 2497-2506.
42. Mohammad RM, Wang S, Banerjee S, Wu X, Chen J, et al. (2005) Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. Pancreas 31: 317-324.
43. Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, et al. (2005) Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 4: 13-21.
44. Humbert M, Casteran N, Letard S, Hanssens K, Iovanna J, et al. (2010) Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS One 5: e9430.
45. Voutsadakis IA, (2011) Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol 3: 153-164.
46. Youle RJ, Strasser A, (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
47. Volate SR, Kawasaki BT, Hurt EM, Milner JA, Kim YS, et al. (2010) Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells. Mol Cancer Ther 9: 461-470.
48. Jiang J, Ye W, Lin YC, (2009) Gossypol inhibits the growth of MAT-LyLu prostate cancer cells by modulation of TGFbeta/Akt signaling. Int J Mol Med 24: 69-75.
49. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, et al. (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and-10 in a caspase-9-dependent manner. J Cell Biol 144: 281-292.
50. Mandic A, Viktorsson K, Strandberg L, Heiden T, Hansson J, et al. (2002) Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. Mol Cell Biol 22: 3003-3013.
51. Chua BT, Guo K, Li P, (2000) Direct cleavage by the calcium-activated protease calpain can lead to inactivation of caspases. J Biol Chem 275: 5131-5135.
52. Tan Y, Dourdin N, Wu C, De Veyra T, Elce JS, et al. (2006) Ubiquitous calpains promote caspase-12 and JNK activation during endoplasmic reticulum stress-induced apoptosis. J Biol Chem 281: 16016-16024.